**Background of MPL Antibodies**
The *MPL* gene encodes the thrombopoietin receptor (TPOR or CD110), a key cytokine receptor regulating megakaryopoiesis and platelet production. MPL, a member of the hematopoietic cytokine receptor superfamily, activates downstream signaling pathways like JAK-STAT upon binding to thrombopoietin (TPO), promoting hematopoietic stem cell maintenance and megakaryocyte differentiation.
MPL antibodies are critical tools in studying myeloproliferative neoplasms (MPNs), as *MPL* mutations (e.g., W515L/K) are drivers of disorders like essential thrombocythemia and primary myelofibrosis. These gain-of-function mutations lead to ligand-independent receptor activation, aberrant cell proliferation, and disease progression. Antibodies targeting MPL are used to detect receptor expression, assess mutational status, and investigate signaling abnormalities in research and diagnostics.
Additionally, MPL antibodies have therapeutic implications. For example, they may block pathogenic signaling in MPNs or enhance platelet production in thrombocytopenia. Their development also supports advancements in understanding TPO/MPL interactions and their roles in hematologic health and disease. Overall, MPL antibodies serve as vital reagents in both basic research and clinical applications related to platelet biology and hematopoietic disorders.